Key result
MODAS study protocol will track 5-year progression from moderate to severe aortic stenosis using multimodal phenotyping.
Why the study?
Predicting progression from moderate to severe calcific aortic stenosis remains challenging because conventional echocardiographic parameters incompletely capture the biological heterogeneity underlying disease progression.
Cohort
Yes
The MODAS study protocol establishes a prospective, deeply phenotyped longitudinal cohort to identify multimodal imaging, inflammatory, and genetic predictors of progression from moderate to severe calcific aortic stenosis.
Answers are grounded in this paper and cite their sources.
Moderate AS with cardiac damage carries clinically relevant risk; leaves open optimal monitoring or intervention timing in this heterogeneous subgroup.
Background: Calcific aortic stenosis (AS) is one of the most common and prognostically relevant valvular heart diseases, with a growing global burden driven by population ageing. Prediction of disease progression from moderate to severe AS, which would be instrumental for earlier diagnosis and treatment, remains challenging. At the same time, moderate AS is increasingly recognized as a heterogeneous condition associated with clinically relevant risk, particularly in patients with cardiac damage, heart failure, or rapid disease progression. Conventional echocardiographic parameters incompletely capture the biological heterogeneity underlying AS progression. The MODAS study was established to investigate biomarkers and mechanisms of AS progression and outcome using longitudinal multimodal phenotyping. Methods: The MODAS Study is a prospective, multicenter, longitudinal observational cohort study enrolling adults with moderate calcific tricuspid AS at three tertiary heart valve centers in Germany. Participants undergo standardized baseline assessment including clinical phenotyping, laboratory testing, electrocardiography, transthoracic echocardiography, cardiac computed tomography and cardiac magnetic resonance imaging. Biospecimens are collected for biomarker, immunologic, proteomic, and genetic analyses, including genome-wide association studies and assessment of clonal haematopoiesis. Participants are followed annually for up to 5 years with repeat clinical assessment, laboratory testing, and echocardiography. The primary endpoint is time to progression to severe AS according to 2025 ESC/EACTS guideline criteria or aortic valve replacement for severe AS, adjudicated by the local multidisciplinary Heart Team. Secondary endpoints include all-cause mortality and additional clinical outcome trajectories. Multimodal data integration will be used to develop and validate prediction models for disease progression and outcome. Discussion: The MODAS Study will provide a harmonized, deeply phenotyped longitudinal dataset to improve risk stratification in moderate AS and to identify imaging, inflammatory, and genetic markers associated with rapid progression and adverse outcomes. The study is designed to support future personalized surveillance strategies, improved selection for earlier intervention, and mechanistic understanding of calcific AS progression. Trial registration: ClinicalTrials.gov NCT05851209 . Registered on 9 May 2023.
No takes yet. Share an insight, caveat, or question.
Phinicarides et al. (2026) conducted a cohort in Moderate calcific tricuspid aortic stenosis. Longitudinal multimodal phenotyping (clinical, imaging, biomarker, immunologic, proteomic, and genetic analyses) was evaluated on Time to progression to severe aortic stenosis according to 2025 ESC/EACTS guideline criteria or aortic valve replacement for severe aortic stenosis. Longitudinal multimodal phenotyping in the MODAS study protocol will evaluate 5-year progression from moderate to severe aortic stenosis across 3 German centers (no results reported).
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: